John Canales, MD
Interventional Cardiology · Live Oak, TXNPI 1548377088
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 277 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 277 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Philips North America LLC$759
- Novartis$624
- Pfizer$471
- Johnson & Johnson$449
- Amgen$400
- plus $3K from 33 others
Across 2 payments — averaging $1028.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$2K
What the payments were for
- Travel & lodging$6029%
- Food & beverage$6,39191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 49 | $1,405 |
| Philips North America LLC | 10 | $759 |
| Novartis | 37 | $624 |
| Pfizer | 42 | $471 |
| Johnson & Johnson | 14 | $449 |
| Amgen | 16 | $400 |
| Abiomed | 6 | $347 |
| Melinta Therapeutics, LLC | 15 | $269 |
| Merck | 12 | $239 |
| Inari Medical, Inc. | 3 | $216 |
| Angiodynamics, Inc. | 3 | $198 |
| Shockwave Medical, Inc | 4 | $197 |
| Medtronic | 2 | $141 |
| Penumbra, Inc. | 4 | $107 |
| Esperion Therapeutics, Inc. | 6 | $96 |
| Amarin Pharma, Inc. | 5 | $93 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $81 |
| Scpharmaceuticals Inc. | 3 | $76 |
| Biosense Webster, Inc. | 4 | $69 |
| Lantheus Medical Imaging, Inc. | 2 | $66 |
| Atricure, Inc. | 2 | $66 |
| Boehringer Ingelheim | 3 | $64 |
| Heartflow, Inc. | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Cvrx, Inc. | 3 | $52 |
| AstraZeneca | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 2 | $37 |
| GSK | 2 | $37 |
| Acist Medical Systems, Inc. | 1 | $37 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Bayer | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Teleflex LLC | 1 | $18 |
| Avinger Inc. | 1 | $14 |
| Biotronik Inc. | 1 | $13 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| AbbVie | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT D Peripheral$602
- Impella$258
- GENERAL - THERAPIES$225
- AVVIGO Guidance System$141
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$138
- Auryon Laser System 100-120 Vac$132
- OPTICROSS$128
- BodyGuardian$127
- XARELTO$125
- Repatha$122
- GENERAL THROMBECTOMY$114
- Micra$109
- FLOWTRIEVER CATHETER, S$103
- CT THROMBECTOMY SYSTEM KIT$103
How this compares
$6,993 in reported general payments places this provider in the 40th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 262 | $268,647 |
| XareltoRivaroxaban | 92 | $112,927 |
| BrilintaTicagrelor | 91 | $78,921 |
| EntrestoSacubitril/Valsartan | 71 | $69,625 |
| Repatha SureclickEvolocumab | 42 | $41,616 |
| MultaqDronedarone Hcl | 15 | $22,658 |
| Repatha SyringeEvolocumab | 15 | $8,234 |
| Nifedipine ErNifedipine | 162 | $4,791 |
| Metoprolol Succinate | 272 | $3,896 |
| Losartan Potassium | 303 | $3,313 |
| ClopidogrelClopidogrel Bisulfate | 268 | $2,653 |
| Atorvastatin Calcium | 246 | $2,249 |
| Bumetanide | 34 | $2,096 |
| Carvedilol | 206 | $1,669 |
| Metoprolol Tartrate | 264 | $1,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $471 | $268,647262 claims |
| Johnson & JohnsonXarelto | $449 | $112,92792 claims |
| AstraZenecaBrilinta | $51 | $78,92191 claims |
| NovartisEntresto | $624 | $69,62571 claims |
| Sanofi-aventis U.S. LLCMultaq | $48 | $22,65815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Live Oak
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
- Peter MonteleoneKyle$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.